Deborah A. Mischke
Pfizer (United States)(US)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Antiplatelet Therapy and Cardiovascular Diseases, Synthesis and biological activity, Synthesis of β-Lactam Compounds, Diabetes Treatment and Management
Most-Cited Works
- → Utility of Complementary Molecular Reactivity and Molecular Recognition (CMR/R) Technology and Polymer-Supported Reagents in the Solution-Phase Synthesis of Heterocyclic Carboxamides(1997)96 cited
- → Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 1)(2005)51 cited
- → Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 2)(2005)48 cited
- → Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y12 Antagonists for Inhibition of Platelet Aggregation(2010)43 cited
- → Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode(2010)35 cited
- → Discovery of Chiral N,N-Disubstituted Trifluoro-3-amino-2-propanols as Potent Inhibitors of Cholesteryl Ester Transfer Protein(2000)30 cited
- → Chiral N,N-Disubstituted Trifluoro-3-Amino-2-Propanols Are Potent Inhibitors of Cholesteryl Ester Transfer Protein(2002)26 cited
- → Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation(2009)25 cited
- → Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation(2009)19 cited
- → Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation(2010)15 cited